Free Trial

Oncolytics Biotech (ONC) Competitors

C$1.49
+0.04 (+2.76%)
(As of 05/24/2024 ET)

ONC vs. SVA, TH, MDNA, HBP, MBX, FRX, HLS, EDT, and QIPT

Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Sernova (SVA), Theratechnologies (TH), Medicenna Therapeutics (MDNA), Helix BioPharma (HBP), Microbix Biosystems (MBX), Fennec Pharmaceuticals (FRX), HLS Therapeutics (HLS), Spectral Medical (EDT), and Quipt Home Medical (QIPT). These companies are all part of the "medical" sector.

Oncolytics Biotech vs.

Oncolytics Biotech (TSE:ONC) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncolytics BiotechN/AN/A-C$28.21M-C$0.40-3.73
SernovaN/AN/A-C$40.73M-C$0.13-2.31

In the previous week, Sernova had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 1 mentions for Sernova and 0 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.18 beat Sernova's score of -0.99 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Oncolytics Biotech Neutral
Sernova Negative

Oncolytics Biotech presently has a consensus target price of C$3.00, indicating a potential upside of 101.34%. Sernova has a consensus target price of C$1.50, indicating a potential upside of 400.00%. Given Sernova's higher possible upside, analysts clearly believe Sernova is more favorable than Oncolytics Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncolytics Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sernova
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Oncolytics Biotech received 188 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 75.38% of users gave Oncolytics Biotech an outperform vote.

CompanyUnderperformOutperform
Oncolytics BiotechOutperform Votes
196
75.38%
Underperform Votes
64
24.62%
SernovaOutperform Votes
8
88.89%
Underperform Votes
1
11.11%

Oncolytics Biotech's return on equity of -115.80% beat Sernova's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncolytics BiotechN/A -115.80% -63.83%
Sernova N/A -183.58%-79.96%

1.9% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 0.1% of Sernova shares are owned by institutional investors. 3.9% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 12.7% of Sernova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncolytics Biotech has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Summary

Oncolytics Biotech beats Sernova on 8 of the 15 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONC vs. The Competition

MetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$112.38MC$425.72MC$5.14BC$5.46B
Dividend Yield0.31%3.48%2.78%5.57%
P/E Ratio-3.7362.73149.9023.18
Price / SalesN/A15,438.942,485.082,333.12
Price / Cash4.2211.3136.1479.98
Price / Book4.816.815.373.11
Net Income-C$28.21M-C$28.78MC$106.43MC$287.80M
7 Day Performance-1.32%0.39%-1.28%-0.83%
1 Month PerformanceN/A4.64%3.24%2.80%
1 Year Performance-49.15%0.00%5.12%31.07%

Oncolytics Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVA
Sernova
0.6817 of 5 stars
C$0.31
-6.2%
C$1.50
+391.8%
-65.9%C$92.54MN/A-2.351,959Gap Up
TH
Theratechnologies
0.8587 of 5 stars
C$1.77
flat
C$5.50
+210.7%
+42.4%C$81.39MC$78.10M-2.24103News Coverage
Positive News
Gap Down
MDNA
Medicenna Therapeutics
0 of 5 stars
C$2.37
+4.4%
N/A+206.5%C$177.23MN/A-10.3016
HBP
Helix BioPharma
0 of 5 stars
C$0.21
flat
N/A+0.0%C$48.18MN/A-7.009News Coverage
MBX
Microbix Biosystems
0 of 5 stars
C$0.34
+3.1%
N/A-22.0%C$46.04MC$22.42M11.17N/APositive News
FRX
Fennec Pharmaceuticals
0 of 5 stars
C$9.75
+2.5%
N/A-8.1%C$264.23MC$21.25M-11.8929
HLS
HLS Therapeutics
0 of 5 stars
C$3.90
-1.0%
C$3.88
-0.6%
-9.1%C$124.37MC$63.07M-3.3691
EDT
Spectral Medical
0 of 5 stars
C$0.50
flat
N/A+47.0%C$139.29MC$1.60M-8.3329News Coverage
High Trading Volume
QIPT
Quipt Home Medical
1.0985 of 5 stars
C$4.33
+1.6%
C$10.87
+151.0%
N/AC$184.33MC$241.33M-28.87N/A

Related Companies and Tools

This page (TSE:ONC) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners